SCM
NMRA icon

Sio Capital Management’s Neumora Therapeutics NMRA Stock Holding History

Sio Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-636,300
Closed -$6.74M – 59
2024
Q4 		$6.74M Buy
+636,300
New +$7.63M 1.9% 20

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Sio Capital Management's NMRA Position: Q1 2025 in Review

Sio Capital Management sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 636,300 shares — an estimated $6.74M sold.

Sio Capital Management first reported a position in NMRA in Q4 2024 and held it in 1 quarter. The position peaked at $6.74M in Q4 2024. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

  • Sio Capital Management reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Sio Capital Management sold 636,300 Neumora Therapeutics shares in Q1 2025, an estimated $6.74M.
  • Sio Capital Management first reported a position in Neumora Therapeutics in Q4 2024 and held it in 1 quarter.
  • Sio Capital Management's Neumora Therapeutics position peaked at $6.74M in Q4 2024.
  • 115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on Sio Capital Management's 13F filing for Q1 2025, filed 15 May 2025.